晚期子宫内膜癌初次肿瘤细胞减灭术的系统综述与荟萃分析
该系统综述与荟萃分析纳入34项研究,评估晚期子宫内膜癌患者接受初次肿瘤细胞减灭术后的残留病灶比例及其与生存的关系。结果显示52.1%达到无肉眼残留,75%达到残留<1cm;任何肉眼残留和残留≥1cm均与更差的无进展生存和总生存显著相关。
要点
- 晚期子宫内膜癌初次减灭术后52.1%达无肉眼残留,75%达残留<1cm。
- 任何肉眼残留与更差无进展生存(HR 2.16)和总生存(HR 2.57)相关。
- 残留≥1cm与更差无进展生存(HR 2.55)和总生存(HR 2.62)相关。
核心结论
- 晚期子宫内膜癌初次细胞减灭术后相当比例患者有残留病灶,残留病灶与更差生存相关。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Scopus至2020年9月11日,纳入34项研究。
- 纳入标准为全文英文报告、≥10例晚期子宫内膜癌患者接受初次细胞减灭术并报告残留病灶与生存。
主要发现
- 52.1%患者达到无肉眼残留(18项研究,1329例),75%达到残留<1cm(27项研究,2343例)。
- IV期研究较III-IV期混合研究减灭比例更低:无肉眼残留41.4% vs 69.8%,残留<1cm 63.2% vs 82.2%。
- 任何肉眼残留 vs 无肉眼残留:无进展生存HR 2.16(95%CI 1.45-3.21,I2=68%),总生存HR 2.57(95%CI 2.13-3.10,I2=1%)。
- 残留≥1cm vs <1cm:无进展生存HR 2.55(95%CI 1.93-3.37,I2=63%),总生存HR 2.62(95%CI 2.20-3.11,I2=15%)。
- 仅限高质量研究的敏感性分析结果一致。
关键数值与推荐
- 最大程度减灭定义为无肉眼残留,最佳减灭定义为残留<1cm或<2cm。
临床怎么用
- 晚期子宫内膜癌初次细胞减灭术应致力于达到无肉眼残留或残留<1cm以改善生存。
- 需在前瞻性试验中进一步研究新辅助化疗与初次细胞减灭术的作用。
局限性
- 纳入研究为回顾性队列,异质性可能影响结果。
- 组织学类型和分期混合,减灭比例在IV期与III-IV期混合研究间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endometrial cancer uncommonly presents at an advanced stage and little prospective evidence exists to guide the management thereof. We aimed to summarize the evidence about primary cytoreductive surgery in the treatment of advanced stage endometrial cancer. DATA SOURCES: MEDLINE, Embase, and Scopus databases were searched from inception to September 11, 2020, using search terms representing the themes "endometrial cancer," "advanced stage," and "primary cytoreductive surgery." STUDY ELIGIBILITY CRITERIA: We included full-text, English reports that included ≥10 patients undergoing primary cytoreductive surgery for advanced stage endometrial cancer and that reported on the outcomes of primary cytoreductive surgery and survival rates based on the residual disease burden. METHODS: Two reviewers independently screened the studies and with disagreements between the reviewers resolved by a third reviewer. Data were extracted using a standardized form. The percentage of cases reaching maximal (no gross residual disease) and optimal (<1 cm or <2 cm residual disease) cytoreduction were assessed by summing binomials proportions, and the association with survival was assessed using an inverse variance-weighted meta-analysis of logarithmic hazard ratios. RESULTS: From 1219 unique records identified, 34 studies were selected for inclusion. Studies consisted of single or multi-institutional cohorts of patients collected over a period of 6 to 24 years and included various mixes of histologies (endometrioid, serous, clear cell, and carcinosarcoma) and disease stages (III or IV). In a meta-analysis of the extent of residual disease after primary cytoreductive surgery, we found that 52.1% of cases reached no gross residual disease status (n=18 studies; 1329 patients) and 75% reached <1 cm residual disease status (n=27 studies; 2343 patients). The proportion of cytoreduction for both thresholds was lower for studies of stage IV vs stage III to IV disease (41.4% vs 69.8% for no gross residual disease; 63.2% vs 82.2% for <1 cm residual disease) but did not vary notably by histology. In a meta-analysis of the reported hazard ratios, submaximal (any gross residual disease vs no gross residual disease) and suboptimal (≥1 cm vs <1 cm) cytoreduction thresholds were associated with worse progression-free survival (submaximal hazard ratio, 2.16; 95% confidence interval, 1.45-3.21; I2=68%; suboptimal hazard ratio, 2.55; 95% confidence interval, 1.93-3.37; I2=63%) and overall survival rates (submaximal hazard ratio, 2.57; 95% confidence interval, 2.13-3.10; I2=1%; suboptimal hazard ratio, 2.62; 95% confidence interval, 2.20-3.11; I2=15%). Sensitivity analyses limited to high-quality studies demonstrated consistent results. CONCLUSION: Among cases of advanced stage endometrial cancer undergoing primary cytoreductive surgery, a significant proportion of patients are left with residual disease, which is associated with worse survival outcomes. Further investigations about the roles of neoadjuvant chemotherapy and primary cytoreductive surgery in prospective trials is warranted in this population.
引用
- Albright BB, Monuszko KA, Kaplan SJ, et al. Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021. PMID: 33957111. doi:10.1016/j.ajog.2021.04.254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。